ORGANOIDSCIENCES
Organoidsciences Ltd. develops regenerative therapies in South Korea. It develops ATORM, an adult tissue derived organoid based regenerative medicine platform for the treatment of intractable intestinal ulcers, as well as salivary glands, liver, and uterus disease areas; ODISEI solutions, an organoid-based discovery platform for screening evaluation and identification; and EXPANSION, an organoid-… Read more
ORGANOIDSCIENCES (476040) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2024: -0.597x
Based on the latest financial reports, ORGANOIDSCIENCES (476040) has a cash flow conversion efficiency ratio of -0.597x as of December 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-9.14 Billion) by net assets (₩15.31 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
ORGANOIDSCIENCES - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how ORGANOIDSCIENCES's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
ORGANOIDSCIENCES Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ORGANOIDSCIENCES ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SHIONOGI & CO LTD - Dusseldorf Stock Exchang
DU:SH0
|
0.070x |
|
PortfolioMan AI Alpha Lab Glob Akt kl n
CO:PMIAAN
|
N/A |
|
Keramika Indonesia Assosiasi
JK:KIAS
|
0.007x |
|
SOZAP AB
F:9RI
|
N/A |
|
FUJI HEAVY IND
BE:FUH
|
0.109x |
|
DDTN
BATS:DDTN
|
N/A |
|
Nykredit Invest Bæredygtige Aktier
CO:NYIBDA
|
N/A |
|
SparDanmark Invest Vækst
CO:SDIVKS
|
N/A |
Annual Cash Flow Conversion Efficiency for ORGANOIDSCIENCES (2021–2024)
The table below shows the annual cash flow conversion efficiency of ORGANOIDSCIENCES from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩15.31 Billion | ₩-9.14 Billion | -0.597x | -736.93% |
| 2023-12-31 | ₩-77.34 Billion | ₩-7.25 Billion | 0.094x | -56.47% |
| 2022-12-31 | ₩-39.56 Billion | ₩-8.52 Billion | 0.215x | -30.69% |
| 2021-12-31 | ₩-15.96 Billion | ₩-4.96 Billion | 0.311x | -- |